Proliferating cell nuclear antigen expression in endomyocardial biopsies is predictive of progression of rejection and the need for enhanced immunosuppression.
Salom
R N
RN
Department of Anatomical Pathology, Monash Medical Centre, Clayton, Victoria, Australia.
Maguire
J A
JA
Esmore
D
D
Hancock
W W
WW
D001324:Autoantigens / Q000378:metabolism*; D001706:Biopsy; D004699:Endocardium / Q000276:immunology; D006084:Graft Rejection / Q000175:diagnosis / Q000209:etiology* / Q000276:immunology; D016027:Heart Transplantation / Q000009:adverse effects* / Q000276:immunology* / Q000473:pathology; D006801:Humans; D007165:Immunosuppression Therapy; D019394:Ki-67 Antigen; D007962:Leukocytes / Q000276:immunology / Q000473:pathology; D009206:Myocardium / Q000276:immunology; D009363:Neoplasm Proteins / Q000378:metabolism; D009687:Nuclear Proteins / Q000276:immunology* / Q000378:metabolism; D018809:Proliferating Cell Nuclear Antigen; D015375:Receptors, Interleukin-2 / Q000378:metabolism
D001324:Autoantigens; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D015375:Receptors, Interleukin-2